We are live on ! Find out more
SAGE icon

Sage Therapeutics

Delisted

SAGE was delisted on the 30th of July, 2025.

217 hedge funds and large institutions have $2.14B invested in Sage Therapeutics in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 78 increasing their positions, 72 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more call options, than puts

Call options by funds: $53.2M | Put options by funds: $32.4M

22% more capital inflows, than outflows

Capital inflows: $184M | Capital outflows: $151M

1.74% more ownership

Funds ownership: 83.45% → 85.19% (+1.7%)

8% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 72

4% less funds holding

Funds holding: 227 → 217 (-10)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

47% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 32

Holders
217
Holders Change
-10
Holders Change %
-4.41%
% of All Funds
3.33%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
17
Increased
78
Reduced
72
Closed
32
Calls
$53.2​M
Puts
$32.4​M
Net Calls
+$20.9​M
Net Calls Change
+$39.9​M

SAGE Hedge Fund Activity: Q4 2021 in Review

217 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q4 2021, worth a combined $2.14B — down 1.8% from $2.17B a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of SAGE and 17 opened new positions — a net loss of 15 holders — while 72 trimmed existing stakes and 78 added.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $39.4M. The largest seller was Point72 Asset Management, cutting an estimated $17.6M.

  • 217 institutional investors held Sage Therapeutics (SAGE) as of Q4 2021, down from 227 in Q3 2021.
  • Funds reported $2.14B of Sage Therapeutics stock for Q4 2021, down 1.8% quarter-over-quarter.
  • 17 funds opened new Sage Therapeutics positions in Q4 2021 and 32 closed out, a net change of -15 holders.
  • The largest Sage Therapeutics buyer in Q4 2021 was EcoR1 Capital, an estimated $39.4M added.
  • The largest Sage Therapeutics seller in Q4 2021 was Point72 Asset Management, an estimated $17.6M sold.

Based on aggregated 13F filings for Q4 2021.